Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 29, 1067-1071, May 1, 1969]
© 1969 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DeVita, V. T.
Right arrow Articles by Perry, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DeVita, V. T.
Right arrow Articles by Perry, S.

Relationship of Normal CDF1 Mouse Leukocyte Kinetics to Growth Characteristics of Leukemia L1210

Vincent T. DeVita, Charlene Denham and Seymour Perry

Medicine Branch, National Cancer Institute, NIH, Bethesda, Maryland 20014

Leukocyte kinetics were studied in the CDF1 mouse using liquid scintillation and radioautographic technics. Although the latter method provides more detailed information, the former technic is readily adaptable to experimental manipulations. The kinetics of mouse leukocytes are different from those in man. Either marrow storage and transit times are different or the generation times of mouse marrow progenitor cells is shorter. Data presented in this study and those available in the literature support the latter concept. The selective therapeutic advantage of the mouse marrow cells is probably related to the presence of nonproliferating cells inaccessible to chemotherapy as reported in the literature. Knowledge of both normal and tumor cell kinetics is essential if drug scheduling is to be placed on a more rational basis.

Received 9/26/68. Accepted 1/11/69.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1969 by the American Association for Cancer Research.